The effect of rituximab injection combined with CHOP regimen on serum LDH and β 2-MG levels in patients with non Hodgkin's lymphoma
Objective To investigate the effect of the combination of rituximab injection and cyclophosphamide+hydroxydoxorubicin+oncovin+prednisone(CHOP)regimen on serum lactate dehydrogenase(LDH)and β 2-microglobulin(β 2-MG)levels in patients with non Hodgkin's lymphoma(NHL).Methods A total of 92 NHL patients admitted to the Hematology Department of Fuyang People's Hospital from January 2020 to May 2023 were selected and randomly divided into an observation group(n=46)and a control group(n=46)using a random number table method.The control group received chemotherapy intervention with CHOP regimen;The observation group received intravenous infusion of rituximab injection 1 day before the start of CHOP chemotherapy.After 6 consecutive cycles of treatment(1 cycle for 21 days),the efficacy and adverse reactions,the levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)],T lymphocytes[surface antigen differentiation cluster 4(CD4+),surface antigen differentiation cluster 8(CD8+),CD4/CD8,helper T cells 17(Th17)],vascular endothelial growth factor(VEGF),LDH,and β2-MG of the two groups were compared after treatment.Results The total remission rate of the observation group was 80.43％(37/46),which was higher than that of the control group,which was 60.87％(28/46),and the difference was statistically significant(P＜0.05).Compared with before treatment,TNF-α and IL-6 levels decreased,Th17 and CD8+levels increased in both groups after treatment,and the difference was statistically significant(all P＜0.05);After treatment,the TNF-α and IL-6 levels in the observation group were lower than those in the control group,and Th17 levels were higher than those in the control group,with statistically significant differences(all P＜0.05).Compared with before treatment,the LDH,β2-MG,and VEGF levels in the two groups decreased significantly after treatment(all P＜0.05);After treatment,the LDH,β2-MG,and VEGF levels in the observation group were lower than those in the control group,and the differences were statistically significant(all P＜0.05).The total incidence rates of adverse reactions in the two groups were 86.96％(40/46)and 80.43％(37/46),respectively,with no statistically significant difference(P＞0.05).Conclusions The combination of rituximab injection and CHOP regimen for NHL treatment can effectively alleviate inflammation,improve LDH,β2-MG,VEGF levels,and enhance efficacy.The safety is similar to using CHOP regimen alone,and it is worth promoting and applying.
NETL
NSTL
万方数据
